- Stocks
- Healthcare
- NASDAQ: ALKS

Price (delayed)

$24.66

Market cap

$3.96B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.6

Enterprise value

$4.18B

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by

Alkermes's net income has increased by 32% YoY and by 15% from the previous quarter

The EPS is up by 32% year-on-year and by 14% since the previous quarter

ALKS's quick ratio is up by 2.9% since the previous quarter but it is down by 2.3% year-on-year

Alkermes's gross profit has decreased by 14% YoY

The revenue has contracted by 13% YoY

What are the main financial stats of ALKS

Market
Valuations
Earnings

Shares outstanding

160.45M

Market cap

$3.96B

Enterprise value

$4.18B

Price to earnings (P/E)

N/A

Price to book (P/B)

3.74

Price to sales (P/S)

3.77

EV/EBIT

N/A

EV/EBITDA

615.18

EV/Sales

4

Revenue

$1.04B

EBIT

-$74.09M

EBITDA

$6.8M

Free cash flow

$48.38M

Per share
Balance sheet
Liquidity

EPS

-$0.6

Free cash flow per share

$0.3

Book value per share

$6.6

Revenue per share

$6.54

TBVPS

$10.55

Total assets

$1.88B

Total liabilities

$827.07M

Debt

$429.04M

Equity

$1.05B

Working capital

$640.17M

Debt to equity

0.41

Current ratio

2.75

Quick ratio

2.14

Net debt/EBITDA

32.96

Margins
Efficiency
Dividend

EBITDA margin

0.7%

Gross margin

83.5%

Net margin

-9.1%

Operating margin

-8.8%

Return on assets

-5%

Return on equity

-8.9%

Return on invested capital

-5%

Return on capital employed

-4.9%

Return on sales

-7.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Alkermes stock price performed over time

Intraday

0.12%

1 week

-0.16%

1 month

10.78%

1 year

43.54%

YTD

23.61%

QTD

32.01%

How have Alkermes's revenue and profit performed over time

Revenue

$1.04B

Gross profit

$871.84M

Operating income

-$91.49M

Net income

-$94.63M

Gross margin

83.5%

Net margin

-9.1%

Alkermes's operating income has increased by 33% YoY and by 19% from the previous quarter

Alkermes's net income has increased by 32% YoY and by 15% from the previous quarter

The company's operating margin rose by 23% YoY and by 19% QoQ

The net margin has grown by 22% YoY and by 15% from the previous quarter

What is Alkermes's growth rate over time

What is Alkermes stock price valuation

P/E

N/A

P/B

3.74

P/S

3.77

EV/EBIT

N/A

EV/EBITDA

615.18

EV/Sales

4

The EPS is up by 32% year-on-year and by 14% since the previous quarter

ALKS's P/S is 40% below its 5-year quarterly average of 6.3 but 40% above its last 4 quarters average of 2.7

The revenue has contracted by 13% YoY

How efficient is Alkermes business performance

The ROIC has increased by 44% YoY and by 18% from the previous quarter

The ROA rose by 36% YoY and by 15% QoQ

The return on equity has increased by 31% year-on-year and by 14% since the previous quarter

The ROS is up by 26% year-on-year and by 16% since the previous quarter

What is ALKS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ALKS.

How did Alkermes financials performed over time

Alkermes's total assets is 127% higher than its total liabilities

The current ratio has grown by 9% from the previous quarter and by 2.2% YoY

The company's total liabilities rose by 8% YoY but it fell by 6% QoQ

The debt is 59% less than the equity

The debt to equity is up by 11% YoY and by 8% from the previous quarter

The debt has grown by 9% YoY and by 4.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.